Although SGLT-2 inhibitors and GLP-1 receptor agonists are crucial drugs in the management of type 2 diabetes, their potential role in delaying the progression of diabetes in prediabetic patients is yet to be discovered. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.